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Cas-Br-M murine leukemia virus (MuLV) is a slow-transforming retrovirus that potently induces leukemias in mice and
therefore is well suited for retroviral insertional mutagenesis. We used Cas-Br-M MuLV in NIH/Swiss mice to establish a new
panel of mainly myeloid leukemias. All tumors found in leukemic animals were classified by gross pathology, morphology, and
immunophenotype, as well as the incidence of known common virus integration sites (VISs) in MuLV-induced myeloid
malignancies (i.e., Evi1, Evi11/Cb2, Evi12, Fli1, and c-Myb). Interestingly, male mice were more susceptible than females to
the induction of leukemia by Cas-Br-M MuLV. Seventy-four of the Cas-Br-M MuLV-inoculated mice developed a severe
splenomegaly, sometimes in association with a thymoma. Although most of the immunophenotyped Cas-Br-M MuLV tumors
were of myeloid origin (58%), numerous T-cell leukemias (21%) and mixed myeloid/T-cell leukemias (21%) were found. The
myeloid leukemias and myeloid compartment of the mixed leukemias were further characterized by immunophenotyping with
stem cell-, myeloid-, and erythroid-specific antibodies. The known Cas-Br-M MuLV common VISs (Evi1, Evi11/Cb2, and Evi12)
were demonstrated in 19%, 12%, and 20% of the cases, respectively, whereas no Fli1 and c-Myb rearrangements were found.
Integrations into Evi1 were restricted to myeloid leukemias, whereas those in Evi11/Cb2 and Evi12 were identified in myeloid
as well as T-lymphoid leukemias. This panel of well characterized Cas-Br-M MuLV-induced hematopoietic tumors may be
useful for the isolation and characterization of new proto-oncogenes involved in myeloid or T-cell leukemias. © 2000 Academic
Press
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Slow-transforming retroviruses that do not contain on-
cogenes in their genome induce tumors by means of
insertional mutagenesis (Ihle et al., 1990; Jonkers and
erns, 1996; Wolff, 1997). The identification of common
irus integration sites in retrovirally induced tumors pro-
ides a powerful strategy to isolate novel transforming
enes from leukemias and lymphomas (Ihle et al., 1990;
onkers and Berns, 1996; Wolff, 1997). Moreover, genes
ocated on chromosomal breakpoint regions or aber-
antly expressed in human hematopoietic malignancies
ave frequently been identified through retroviral inser-
ional mutagenesis in murine leukemias [e.g., Evi1 (Mor-
ishita et al., 1990, 1988), Evi2 (NF1) (Buchberg et al., 1990;
Shannon et al., 1994; Side et al., 1998), Evi6 (Hoxa9)
(Nakamura et al., 1996a,b), BclI (cyclin D1) (de Boer et al.,
1997; Silver and Buckler, 1986), N-Myc (Hirvonen et al.,
1993; Setoguchi et al., 1989), and Erg (Shimizu et al.,
1993; Valk et al., 1997b)]. The molecular basis of retroviral
insertional mutagenesis in the development of leuke-
mias is the activation of proto-oncogenes or inactivation
of tumor suppressor genes as a result of proviral inte-
1 To whom reprint requests should be addressed. Fax: 31104089470.
-mail: Delwel@hema.fgg.eur.nl.
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308gration into the host genome. Generally, expression of
proto-oncogenes located in the vicinity of an inserted
provirus is elevated by retroviral promoter or enhancer
sequences. However, retroviral integration within the
protein-coding region of a cellular target gene resulting
in the expression of truncated products has also been
observed (Jonkers and Berns, 1996; Wolff, 1997).
Cas-Br-M MuLV leukemia virus (also referred to as Cas-
Br-E MuLV) is a naturally occurring ecotropic virus that
induces a wide variety of hematological diseases in NFS
mice (Holmes et al., 1986) and non-B-, non-T-cell leukemias
in NIH/Swiss mice (Bergeron et al., 1991). A number of
recurrent targets have been observed: Evi1 (Bergeron et al.,
1993; Morishita et al., 1988; Mucenski et al., 1988), Evi11/
Cb2 (Valk et al., 1997a), Evi12 (Valk et al., 1999), and Fli1
(Bergeron et al., 1991) or, for Moloney and Friend MuLV [i.e.,
c-Myb (Nason-Burchenal and Wolff, 1993; Nazarov and
Wolff, 1995; Shen-Ong and Wolff, 1987)]. Evi1 encodes a
zinc-finger transcription factor (Morishita et al., 1988), and
overexpression of Evi1 has been shown to interfere in
granulocytic (Morishita et al., 1992) as well as erythroid
differentiation (Kreider et al., 1993). Evi11 and Evi12 are two
relatively novel common VISs that we recently identified in
the Cas-Br-M MuLV-induced interleukin-3-dependent my-
eloid cell line NFS107 and the Cas-Br-M MuLV-induced
primary tumors described in this report (Valk et al., 1997a,
1999). Evi11 is located on mouse chromosome 4, and the
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309Evi1, Evi11/Cb2, and Evi12 in Cas-Br-M MuLV-INDUCED LEUKEMIAStarget proto-oncogene in this locus is the gene encoding
the hematopoietic peripheral cannabinoid receptor Cb2
(Valk et al., 1997a). The candidate proto-oncogene in Evi12,
hich was mapped onto mouse chromosome 10 (Valk et
al., 1999), is currently unknown. The ets-transcription factor
Fli1 was originally identified by cloning proviral insertions
from Friend MuLV-induced erythroid leukemias (Ben-David
et al., 1990), but proviruses in Fli1 were later also shown in
on-B-, non-T-cell leukemias (Bergeron et al., 1991). The
ranscription factor c-Myb is one of the best-studied proto-
ncogenes in myeloid disease (Introna et al., 1994) and has
een shown to be a target for proviral insertions in myeloid
eukemias (Wolff, 1997)
To isolate novel common VISs and identify new target
roto-oncogenes and cooperating proto-oncogenes
Valk et al., 1999) involved in myeloid leukemia develop-
ent, we generated a novel panel of Cas-Br-M MuLV-
nduced leukemias in NIH/Swiss mice. We characterized
he hematological malignancies by gross pathology, cy-
ology, and immunophenotyping using a panel of mono-
lonal antibodies (MAbs) directed to cell surface anti-
ens of various blood cell lineages. Seventy-four of the
1 animals presenting with a hematopoietic disease
ere leukemic, manifested by a splenomegaly and/or a
hymoma. Although the majority of the leukemias were of
yeloid origin (59%), a significant number of the leuke-
ias expressed a T-cell phenotype (21%) or a mixed
yeloid/T-cell phenotype (21%). We also determined the
requencies of proviral insertion in loci that have previ-
usly been shown to be recurrent targets in myeloid
alignancies for Cas-Br-M MuLV. Here, we demonstrate
requent retroviral insertion in Evi1, Evi11, and Evi12 but
ot in Fli1 and c-Myb. Retroviral insertion in relation to
he immunophenotype of the Cas-Br-M MuLV-induced
eukemias has been investigated.
This well characterized panel of retrovirally induced
eukemias provides a powerful source for the isolation of
ovel transforming proto-oncogenes involved in myeloid
nd T-cell leukemia development.
RESULTS
eukemia development and gross pathology
TABLE 1
Frequency of Cas-Br-M MuLV-Induced Leukemias
in NIH/Swiss Mice
No. of mice No. of leukemias Frequency (%)
Males 54 41 76
Females 62 33 53
Total 116 74 64Tumor incidence, gross pathology, and histology. New-
orn NIH/Swiss mice were inoculated with Cas-Br-M
t
CuLV-containing culture supernatant. Ninety-one of the
16 mice that were inoculated developed hematological
alignancies, with 74 of these becoming severely sick
ith signs of splenomegaly and/or a thymoma (Table 1).
he other 17 mice developed a mild disease, with a
oderate increase (twofold) in spleen size. Eighteen of
he 25 mice without evidence of hematological disease
ied of unknown causes. The remaining 7 mice (females)
ere sacrificed at the end of the experiment (i.e., after
94 days), without signs of leukemia or any other dis-
ase.
Cytological analysis of mice with splenomegaly alone
evealed immature blast cells (46%), myeloblasts with
ranulocytic features (27%), or lymphocytes (27%). In 82%
f the mice with a thymoma histology, the presence of a
igh percentage of lymphocytes was observed, whereas
he remaining (18%) contained immature blast cells with-
ut signs of granulocytic differentiation.
Differences between male and female mice. In this
tudy, we focused on the 74 cases with severe hemato-
ogical malignancies. Interestingly, only 33 of 62 (53%)
emale mice developed severe leukemia, whereas tumor
ormation in male mice was evident in 41 of 54 (76%)
ases. Furthermore, male mice developed leukemia
ore rapidly than female mice (Fig. 1). Thus male NIH/
wiss mice appear to be more susceptible to leukemia
nduction by Cas-Br-M MuLV than female animals. In
ontrast, gross pathology revealed no significant differ-
nces between sexes in the leukemia types found (Table
). Thirty-one of 41 male mice (71%) and 24 of 33 females
73%) manifested leukemia with a major spleen enlarge-
ent, whereas in 10 of 41 males (24%) and 7 of 33
emales (21%), the mice also developed a thymoma. Two
emales developed thymoma without splenomegaly.
FIG. 1. Survival curves of male (—) and female (- - -) NIH/Swiss mice
developing leukemia after inoculation with Cas-Br-M MuLV. A log-rank
test was performed, based on Kaplan-Meier analysis. Males died
significantly earlier than females (P , 0.001). The x-axis represents the
ime at which the mice developed leukemia after injection with the
as-Br-M MuLV.
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310 JOOSTEN ET AL.Phenotype of Cas-Br-M MuLV-induced leukemias
Leukemic cells from spleen, thymus, or bone marrow
of 63 of the 74 cases with severe disease could be
immunophenotyped by flow cytometry using MAbs (Ta-
ble 3).
T-cell leukemias. Thirteen cases displayed a solely
T-cell phenotype [i.e., CD311/Thy111 (11 cases), CD311/
hy12 (1 case) or CD32/Thy111 (1 case)], without expres-
ion of myeloid markers (Fig. 2 and Table 4). In 10 of
hose mice, the T-cell origin of the leukemia was sub-
tantiated by the presence of a thymoma (Table 4). In 13
ases, the leukemic cells expressed T-cell as well as
yeloid markers, with 8 of these displaying a thymus
nlargement as well.
Myeloid leukemias. A CD32/Thy12 or CD32/Thy11
non-T-cell phenotype (Fig. 2 and Table 4) was found in 37
cases. Thirty-six of those 37 cases displayed a major
spleen enlargement without a thymoma. These leuke-
mias and the nonlymphoid compartment of the 13 mixed
leukemias, containing both CD311/Thy111 and CD32
cells, were further immunophenotyped using the com-
plete panel of MAbs (Table 3), which revealed heteroge-
neity among the cases. Six cases (5 non-T-cell and 1
mixed leukemia) showed an immature myeloid pheno-
type, that is, Imm1 (Sca1, Thy11, ER-MP581, and/or ER-
T
Gross Pathology of Cas-B
Sex Gross pathology
Males Splenomegaly
Thymus enlargement
Splenomegaly and thymus enlargement
Total
emales Splenomegaly
Thymus enlargement
Splenomegaly and thymus enlargement
Total
T
Monoclo
Antibody Antigen
ER-MP54 ER-MP54 Ag Myeloid cells
ER-MP58 ER-MP58 Ag Myeloid cells
M1/70 Mac1 Nonfixed macrophage
F4/80 F4/80 Ag Macrophages
RB68C5 Gr1 Granulocytes
ER-MP21 Transferrin receptor Cells in cycle, erythro
TER119 Glycophorin A Mature erythroid cells
59-AD2.2 Thy1 T-cells, hematopoietic
KT3 CD3 Mature functional T-c
RA3 6B2 B220 B-cells, myeloid cells
E13 161-7 Sca1 Hematopoietic precursors, TMP541), Gr12, Mac12, and F4/802 (Table 5). Four cases
revealed a myeloid phenotype with neutrophil character-
istics, that is, Imm1, Gr1 (Mac11), but F4/802. Myeloid
eukemias expressing monocyte/macrophage differenti-
tion markers, that is, Imm1, F4/801, Mac11, but Gr12
were identified in 16 (11 non-T-cell and 5 mixed leuke-
mias) cases. Twelve (9 non-T-cell and 3 mixed leuke-
mias) cases expressed monocytic as well as granulo-
cytic differentiation markers (i.e., Imm1, F4/801, Mac11,
nd Gr11). In 10 cases, myeloid and erythroid differenti-
tion markers (ER-MP211 and Ter1191) were identified.
In 2 of the 37 non-T-cell leukemia cases, mainly B2201
lymphocytes were found. Although these data suggest
that these leukemias are of B-lymphocyte origin, no re-
arrangements in the immunoglobulin heavy chain genes
were found using a Jh probe on EcoRI-digested genomic
DNAs of these cells (data not shown). In fact, no rear-
rangements in the IgH gene were found in any of the
other cases (data not shown).
Retroviral integrations in Cas-Br-M MuLV-induced
leukemias
Cas-Br-M MuLV-associated common VISs. Loci previ-
ously shown to be targets for Cas-Br-M provirus are Evi1
(Bergeron et al., 1993, 1992; Morishita et al., 1988; Mu-
uLV-Induced Leukemias
of mice %
Latency period
(days) Mean
31 76 166–299 215
0 0
10 24 137–236 197
41 100 137–299 211
24 73 170–394 263
2 6 175–224
7 21 177–314 245
33 100 170–394 245
tibodies
ficity Reference
Leenen et al., 1990b
Leenen et al., 1990b
ulocytes, natural killer cells Springer et al., 1979
Austyn and Gordon, 1981
Hestdal et al., 1991
Leenen et al., 1990a
Ikuta et al., 1990
cells, myeloid cells Ledbetter and Herzenberg, 1979
Tomonari, 1988
Coffman, 1982ABLE 2
r-M M
No.ABLE 3
nal An
Speci
s gran
id cells
stem
ells-cells Aihara et al., 1986
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311Evi1, Evi11/Cb2, and Evi12 in Cas-Br-M MuLV-INDUCED LEUKEMIAScenski et al., 1988), Evi11/Cb2 (Valk et al., 1997a), Evi12
Valk et al., 1999), and Fli1 (Bergeron et al., 1991),
hereas Moloney and Friend MuLV also target c-Myb
Nason-Burchenal and Wolff, 1993, 1995; Shen-Ong and
olff, 1987). To study the frequencies of rearrangements
n these loci, Southern blot analysis was carried out on
FIG. 2. Immunophenotyping of Cas-Br-M MuLV-induced primary CSL
umors. Representatives of leukemias with a T-cell phenotype (Thy111
and CD311) (A, CSL38) and with a non-T-cell phenotype (CD32 and
hy11 or 2) (B, CSL60). CSL60 is a typical example of a leukemia type IV
(see Table 5) (i.e., blasts with granulocytic and monocytic differentia-
tion).pleen and/or thymus DNA obtained from the 74 mice
ith severe disease. Rearrangements in Evi1, Evi11, or
o
Evi12 were found in 28 cases (Fig. 3). No abnormalities in
li1 or c-Myb were observed. In 48 of 74 cases, no
etroviral insertions in any of these regions could be
dentified.
Evi1. Rearrangements in the Evi1 gene were found in
4 of 74 cases (Figs. 3 and 4A). Those novel retroviral
nsertions in the Evi1 locus are situated in the same
egion of the Evi1 locus, as the previously described
as-Br-M MuLV Evi1 insertions (Fig. 4B) (Bartholomew et
l., 1989; Bergeron et al., 1993; Valk et al., 1997b). Evi1
earrangements were demonstrated in non-T-cell or
ixed lineage leukemias and not in T-cell leukemias
Table 6). Two leukemias expressed an immature immu-
ophenotype, one leukemia showed monocytic differen-
iation, a fourth leukemia expressed granulocytic mark-
rs, and two other leukemias coexpressed monocytic as
ell as granulocytic characteristics. Interestingly, five
eukemias showed an erythroid phenotype (i.e., the cells
ere ER-MP21 and TER119 positive; Table 5). Three
ice, from which the tumors were later shown to have
vi1 rearrangements, died before any viable cell could
e harvested and immunophenotyped.
Evi11/Cb2. The target gene in Evi11 has been shown to
e Cb2. Retroviral insertions in Cb2 occur either 59 or 39
f the protein-coding region (Valk et al., 1997a, 1999).
earrangements in Evi11/Cb2 were found in 9 of the 74
ases studied (Fig. 3). The exact positions of these Evi11
etroviral insertion sites have been documented recently
Valk et al., 1999). Evi11 rearrangements were found in
-cell, myeloid, or mixed leukemias (Table 6). Three Evi11
earrangements were found in leukemic spleens ob-
ained from mice that died before immunological analy-
is could be carried out. Interestingly, in addition to the
ine leukemic cases, Southern blot analysis revealed
earrangements in the Evi11/Cb2 locus in splenic DNA
rom 2 of the 17 cases with a mild disease (i.e., CSL74
nd CSL75).
Evi12. Evi12 rearrangements occurred in 15 of the 74
eukemic cases (Fig. 3). Those proviral insertions are all
resent in a relatively small 1600-bp region, located
pstream of the Tra1/Grp94 gene, and have been de-
cribed recently (Valk et al., 1999). The target gene in
vi12 is currently unknown. As with Evi11/Cb2 rearrange-
ents, retroviral insertions in Evi12 have been found in
-cell (three cases), non-T-cell (two cases), and mixed
eukemias (four cases) (Table 6). Of the 74 mice that
eveloped a severe leukemia, five died before any viable
ell could be harvested. Interestingly, all five mice car-
ied a retroviral insertion in Evi12.
Tumors with multiple rearrangements. Coincidence of
vi1 with other integrations appeared to be rare: Evi1
nd Evi11/Cb2 in one case and Evi1 and Evi12 in two
ases, whereas Evi1, Evi11/Cb2, and Evi12 were also
bserved in one case (Fig. 3). Interestingly, six of the
vi11/Cb2 rearranged cases also harbored Evi12 virus
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312 JOOSTEN ET AL.integrations (Fig. 3). These data may suggest coopera-
tion in leukemia development between Cb2 and the
target gene in the Evi12 locus. Only three of those cases
ould be analyzed phenotypically. One leukemia had a
-cell phenotype (CSL14), and two mixed leukemias ex-
ressed T-cell as well as myeloid markers (CSL12 and
SL16).
DISCUSSION
Cas-Br-M MuLV-injected newborn NIH/Swiss mice de-
eloped detectable leukemias by approximately 140–400
ays postinoculation. Most of these were myeloid leuke-
ias (59%), although T-cell (21%) and mixed T-cell/my-
loid (21%) leukemias were found. These results differ
omewhat from other studies. Cas-Br-M induced a wide
pectrum of hematopoietic neoplasias in NFS/N mice,
ncluding T-, pre-B-, and B-cell lymphomas as well as
rythroid, myeloid, and megakaryocytic leukemias
Holmes et al., 1986, 1985). Bergeron et al. (1993, 1992,
1991) reported the development of mainly non-T-, non-B-
cell lymphomas in NIH/Swiss mice after injection with
T
Immunophenotyping of Cas-Br-M MuLV-Induc
Immunophenotype
T-cell leukemias CD311/Thy111
on-T-cell leukemiasd CD32/Thy12 or 1
ixed leukemiase CD311/Thy111 and CD32/Thy12 o
Not evaluable
Total
a Mice with a thymoma include cases with or without a splenomega
b In one case (CSL70), CD311/Thy12 lymphocytes were found.
c In one case (CSL54), CD32/Thy111 lymphocytes were observed.
d CD32 non-T-cell leukemias Thy2 or Thy11 but not Thy111 cells.
e Mixed leukemias contain CD311/Thy111 T-lymphocytes as well as
T
Immunophenotyping of Non-T-Cell Leukemias
Leukemia type Immun
I: Immature blast cells Gr12, F4/802, M
II: Blasts with neutrophilic differentiation Gr11, F4/802, (
III: Blasts with monocytic differentiation Gr12, F4/801, M
IV: Blasts with granulocytic and
monocytic differentiation
Gr11, F4/801, M
V: Blasts with myeloid and
erythroid differentiation
ER-MP211, TER
(Mac11), (F4
VI: B-lymphocytic B2201 and oth
Total
Note. Leukemias were immunophenotyped using the monoclonal an
a (Imm1) indicates that cells may express a combination of Sca1, ER
b Mixed leukemias contain T-lymphocytic as well as non-T-cell leukemia ce
c Expression markers between parentheses may be positive or negative.Cas-Br-E MuLV. In contrast, we observed T-cell and my-
eloid leukemias in the same mouse strain. The major
difference between the two studies is that Bergeron et al.
used a molecular clone NE-8, described by Jolicoeur et
al. (1983), whereas we inoculated a biologically cloned
Cas-Br-M MuLV stock obtained by limiting dilution (Hart-
ley and Rowe, 1976) in the same mouse strain. In con-
trast to our studies, Bergeron et al. (1993, 1992, 1991)
observed frequent insertions of Cas-Br-E MuLV in Fli1,
whereas these investigators observed no Cas-Br-E pro-
virus insertions in either Evi11/Cb2 or Evi12 loci (E. Ras-
sart, personal communication). In fact, only mink cell
focus forming retroviral integrations were identified in
Evi11 and Evi12 (Valk et al., 1999), suggesting the pres-
ence of amphotropic virus contaminant in the Cas-Br-M
stock, which is absent in Cas-Br-E (Ott et al., 1992;
Rasheed et al., 1982) In addition, no rearrangements of
c-Myb were detected in either study, indicating that the
c-Myb locus is a frequent target for Moloney and Friend
MuLV (Nason-Burchenal and Wolff, 1993; Nazarov and
Wolff, 1995; Shen-Ong and Wolff, 1987) but not for Cas-
kemias: T-Cell versus Non-T-Cell Leukemias
Splenomegaly Thymomaa Total
3b 10c 13
36 1 37
5 8 13
11 0 11
55 19 74
leukemia cells.
umber of Evi1-Positive Tumors among Them
typea
Non-T-cell
leukemias
Mixed
leukemiasb
Evi1-positive
leukemias
and Imm1 5 1 2
c and Imm1 4 0 1
and Imm1 11 5 1
and Imm1 9 3 2
Imm1,
nd (Gr11)
6 4 5
2 0 0
37 13 11
s indicated in Table 3.
, ER-MP54, and/or Thy1.ABLE 4
ed Leu
r 1
ly.ABLE 5
and N
opheno
ac12,
Mac1),
ac11,
ac11,
1191,
/801), a
er2
tibodie
-MP58lls. In this case, the non-T-cell compartment is analyzed.
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313Evi1, Evi11/Cb2, and Evi12 in Cas-Br-M MuLV-INDUCED LEUKEMIASBr-type viruses. The results from these studies together
reemphasize that infection with different retroviruses or
even subclones of a particular retrovirus may result in
proviral integration in distinct loci, thereby determining
the development of selective types of leukemia or lym-
phoma (Jonkers and Berns, 1996; Wolff, 1997).
More males then females developed leukemia after
Cas-Br-M MuLV-injection. In fact, seven female mice did
not develop any hematological malignancy at all, even at
13 months after inoculation. Moreover, male mice devel-
oped leukemia more rapidly than did females. Gender-
related sensitivity to tumor-inducing agents in rodents
has been documented in several tumorigenic conditions
FIG. 3. Common virus integration sites Evi1, Evi11/Cb2, and Evi12 in
Evi1, Evi11/Cb2, and Evi12 in the primary CSL tumors. Overlapping box
(i.e., Evi1, Evi11/Cb2, and/or Evi12). In each box, the CSL leukemia nupreviously. For instance, female animals have been re-
ported to be more sensitive to certain tumor-inducingagents or viruses (Siglin et al., 1995; Storch and Chused,
984), whereas other studies have demonstrated a
igher tumor incidence in males after exposure to radi-
tion (Di Majo et al., 1996; Yoshida et al., 1993). As an
nteresting parallel to our study, the radiation-induced
umors, showing greater susceptibility in male mice, rep-
esent cases of acute myeloid leukemia (Di Majo et al.,
996; Yoshida et al., 1993). Explanations to clarify these
ender-specific differences are mainly based on specu-
ation, including possible differences in sensitivity of cer-
ain tumor cells to gender-specific hormones (Siglin et
l., 1995; Yoshida et al., 1993). Although gender-specific
leukemia development is currently not one of the pur-
y CSL tumors. Diagram represents the different provirus insertions in
bolize coincidence of provirus insertions in two or three common VISs
are depicted. The y-axis represents the sum of the leukemias.primarposes of our investigations, the difference in sensitivity
between male and female mice to Cas-Br-M MuLV-in-
Bblack
1985) a
314 JOOSTEN ET AL.duced leukemia progression is intriguing and requires
further study.
Retroviral insertions in the Evi1 locus occurred in my-
FIG. 4. Provirus insertion in the common VIS Evi1. (A) Southern blot an
Filters were hybridized with fragment 1 (B), a cDNA specific for the Ev
arrow indicates the size of the normal allele. All tumors (i.e., CSL23, C
representing the leukemic subpopulation. (B) Schematic representation
H, HindIII). The first three exons of the Evi1 gene are indicated by
MuLV-induced primary CSL tumors and NFS cell lines (Holmes et al.,eloid, erythroid, or mixed myeloid/T-cell leukemias (19%,
14/74). These results are in agreement with many reports
h
lshowing that Evi1 is a proto-oncogene mainly involved in
myeloid leukemia progression (Bartholomew et al., 1989;
ergeron et al., 1993, 1992; Morishita et al., 1988). In
of PstI-, PvuII-, and SstI-digested genomic DNA of primary CSL tumors.
(Valk et al., 1997b). The size marker is depicted in kilobases, and an
CSL30, CSL41, and CSL95) contain rearrangements in the Evi1 locus,
genomic structure of the Evi1 locus (PII, PvuII; B, BamHI; S, SstI; P, PstI;
boxes. The location and orientation of proviruses in the Cas-Br-M
re depicted by arrows.alysis
i1 locus
SL29,
of theumans, EVI1 has shown to be mutated in acute myeloid
eukemias with chromosome 3q26 abnormalities (Mor-
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315Evi1, Evi11/Cb2, and Evi12 in Cas-Br-M MuLV-INDUCED LEUKEMIASishita et al., 1990) and in certain cases of myelodysplas-
tic syndrome (Dreyfus et al., 1995), a preleukemic dis-
ease characterized by a severe anemia. Overexpression
of Evi1 in 32Dcl3 cells has been shown to interfere with
granulocytic differentiation of these cells when stimu-
lated with granulocyte colony-stimulating factor (Mor-
ishita et al., 1992). In addition, Kreider et al. (1993) dem-
onstrated a block of erythroid differentiation by Evi1 in
vitro. Possibly, Evi1 interferes with GATA1, a transcription
actor that is indispensable for erythropoiesis (Pevny et
l., 1995, 1991). Recent studies with Evi1 transgenic mice
lso support this hypothesis (i.e., a defective erythropoi-
sis as a result of Evi1 overexpression) (Louz et al.,
anuscript in preparation). In this study, we show that
vi1 retroviral integrations frequently occur in leukemic
last cells expressing not only myeloid- but also eryth-
oid-specific markers (i.e., ER-MP21 and TER119). These
bservations support the hypothesis that one of the ma-
or effects of aberrantly expressed Evi1 in hematopoietic
recursors is a block of erythropoiesis.
In contrast to Evi1 proviral insertions, retroviral inte-
rations in Evi11/Cb2 (12%, 9/74) and Evi12 (20%, 15/74)
re not lineage restricted. The observations that Evi11/
b2 and Evi12 mutations occurred in T-cell leukemias as
ell as in myeloid leukemias suggest that retroviral in-
ertions in those loci may have occurred early in hema-
opoiesis (i.e., in primitive hematopoietic stem cells).
ubsequently, additional mutations, such as Evi1 retro-
iral insertions, may determine whether myeloid or lym-
hoid leukemias evolve.
Leukemia initiation and progression involve aberrant
xpression of multiple genes (Adams and Cory, 1992).
wo or more VISs have frequently been shown to be
resent in one particular tumor or tumor cell line. For
nstance, Hoxa- and Pbx1-related genes in myeloid leu-
emias (Nakamura et al., 1996b), c-Myc and M-CSF in a
onocyte tumor (Baumbach et al., 1988), IL-3, SCL, and
oxb8 in myeloid WEHI-3B(D2) cells (Tanigawa et al.,
TABLE 6
Common Virus Integration Sites in Cas-Br-M MuLV-Induced
Tumors: Immunologic Characterization
Leukemia type Evi1 Evi11/Cb2 Evi12
T-cell leukemia 0 2 3
Non-T- non-B-cell leukemia 9 1 2
Mixed leukemiaa 2 3 4
Deadb 3 3 5
Total 14 9 15
a Mixed leukemias contain T-lymphocytic as well as non-T-cell leu-
kemia cells.
b Immunophenotype could not be determined due to the high per-
centage of dead cells.994), IL-3 or GM-CSF and c-Myb in WEHI-274 cells
(Leslie et al., 1991), IL-3 and GM-CSF in in vivo-passagedFDC-P1 cells (Duhrsen et al., 1990), p53 and PU.1 in
erythroleukemias (Moreau-Gachelin et al., 1988), and
Fli1 and p53 in non-T-, non-B-cell leukemias (Bergeron et
al., 1993). These data indicate that leukemogenesis, like
oncogenesis in general (Hunter, 1991; Vogelstein and
Kinzler, 1993), is indeed a multistep process involving
mutation of multiple oncogenes (Adams and Cory, 1992).
The simultaneous occurrence of different VISs in the
same infected animal suggests a similar mechanism
underlying murine leukemogenesis. Evi11/Cb2 and Evi12
insertions frequently coincided in the same leukemias,
suggesting that the Cb2 in Evi11 and the currently un-
known Evi12-target oncogene cooperate in leukemia de-
velopment. Here we demonstrate retroviral integration in
Evi1 and Evi11/Cb2 in two cases, CSL13 and CSL23. In
fact, as a result of retroviral insertions in both loci, aber-
rant expression of Evi1 and Evi11/Cb2 has been demon-
strated in the myeloid cell line NFS78 (Valk et al., 1997a).
These results suggest that in certain cases of myeloid
leukemia, these two proto-oncogenes may collaborate in
hematopoietic transformation. This hypothesis will be
directly assessed in vivo by cross-breeding of Evi1- and
Cb2-transgenic mice that we recently generated (unpub-
lished results). Evi1 also appears to collaborate with an
Evi12-related proto-oncogene because three leukemias
contain insertions in both of these loci (i.e., CSL13,
CSL29, and CSL93). Two common VISs that frequently
coincide are Evi11/Cb2 and Evi12, that is, rearrange-
ments were shown in both common VISs in CSL12,
CSL13, CSL16, CSL27, and CSL97. Although the target
gene in Evi12 is currently unknown, the data obtained so
far are highly suggestive for collaboration of Cb2 and a
protooncogene at the Evi12-locus in leukemia progres-
sion. In one leukemia, CSL13, three loci, Evi1, Evi11/Cb2,
and Evi12, harbor Cas-Br-M provirus, which may imply
that indeed three or maybe more genetic defects are
required for full leukemic transformation (Vogelstein and
Kinzler, 1993).
Interestingly, in 18 of the 26 cases, retroviral insertion
was observed in only one locus (i.e., Evi1, Evi11, or
Evi12), and in 48 cases, we did not identify any retroviral
insertion in the loci that we studied. These results sug-
gest that many unknown candidate target genes for
Cas-Br-M provirus are still waiting to be discovered in
our panel of leukemias. Large-scale isolation of retroviral
flanking sequences is currently being carried out in our
series of leukemias using inverse PCR procedures. Nu-
cleotide sequence analysis and differential probing to
gridded high-density filters from a BAC library will be
carried out to identify novel common integration sites
and new (collaborating) proto-oncogenes. These studies
may result in the definition of complementation groups of
transforming genes, which may provide insight into the
defects that may occur in different signaling pathways
leading to full malignant transformation of hematopoietic
cells.
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Mice, viruses, and pathology of tumors
NIH/Swiss mice were obtained from Harlan (Horst,
The Netherlands). Cas-Br-M MuLV-producing NIH 3T3
cells (donated by Dr. Janet W. Hartley, National Institutes
of Health, Bethesda, MA) (Hartley and Rowe, 1976) were
cultured in Dulbecco’s modified Eagle’s medium (GIBCO,
Gent, Belgium) containing 10% FCS. To obtain virus, a
70% subconfluent culture of Cas-Br-M MuLV-producing
NIH 3T3 cells was incubated in 5 ml of culture medium
for 18 h at 37°C in a 75-cm2 culture flask. Newborn
IH/Swiss mice were subcutaneously injected with 100
ml of viral supernatant, made cell free by filtration (pore
size, 0.22 mm; Nucleopore Corp., Pleasanton, CA). Leu-
kemias appeared 5–13 months after inoculation, with
mice sacrificed when moribunded. Leukemic mice had
enlarged spleens, frequently accompanied by gross thy-
mus enlargements. Diagnosis was based on gross pa-
thology, cytological staining with May-Gru¨nwald/Giemsa,
and flow-cytometric analysis using MAbs directed to
membrane surface antigens (Table 3). Leukemias were
also characterized for DNA rearrangements within im-
munoglobulin heavy chain (IgH) genes. Cells were cryo-
preserved in aliquots of 50 3 106 cells in 7.5% DMSO and
0% FCS using a controlled freezing apparatus and
tored in liquid nitrogen.
abeling of cells with MAbs and flow cytometry
Cells were labeled sequentially with rat MAbs fol-
owed by GARa (goat anti-rat)–FITC (Nordic, Tilburg, The
etherlands). All incubations were carried out for 30 min
n ice in PBS supplemented with 1% BSA. The specifi-
ations of the MAbs used in this study are described in
able 1. Cell surface fluorescence was analyzed using a
ACScan flow cytometer (Becton Dickinson, Mountain
iew, CA). A sample was considered positive for a par-
icular marker when 30% or more of the cells showed
ositive fluorescence (Fig. 2). In the case of Thy1 expres-
ion, a discrimination was made between intermediate
ositive (Thy11; not more than 1 log difference in fluo-
rescence intensity between positive and the negative
control) and strongly positive (Thy111; 2 log difference or
more between positive and negative) (Fig. 2).
DNA isolation, Southern blot analysis, and probes
Isolation of genomic DNA and Southern blot analysis
was carried out exactly as described previously (Valk et
al., 1997a). The IgH region was analyzed with an EcoRI–
BglII (2.5-kb) Jh probe from clone H24 (Honjo et al., 1981)
a gift from Dr. T. Honjo, Kyoto University, Japan). The
-cell receptor b-chain gene was analyzed with a 4-kb
HindIII Jb1 probe (Duby et al., 1985). Rearrangements in
the Evi1 locus were detected using the 535-bp cDNA
fragment that we recently described (Valk et al., 1997b),whereas those in the Evi11/Cb2 locus were studied with
a 1.2-kb EcoRI–BamHI Cb2 cDNA fragment (Valk et al.,
1997a). Evi12 rearrangements were studied with the 503
probe obtained with a RT-PCR-based strategy to isolate
cDNA fragments flanking retrovirus integration sites
(Valk et al., 1997b). Rearrangements in the c-Myb gene
were determined with a 450-bp NcoI–EcoRI and a 500-bp
PstI–PstI cDNA probe spanning exons 3–6 of the gene
(Shen-Ong et al., 1986). Fli1 insertions were studied us-
ing a 1.7-kb EcoRI cDNA probe (Ben-David et al., 1991).
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